Literatur
-
1
Hadziyannis S J, Vassilopoulos D.
Complex management issues: management of HCV in the atypical patient.
Baillieres Best Pract Res Clin Gastroenterol.
2000;
14
277-291 (III)
-
2
Pol S, Vallet-Pichard A, Fontaine H. et al .
HCV infection and hemodialysis.
Semin Nephrol.
2002;
22
331-339 (IV)
-
3
Fontana R J.
Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.
Dig Dis.
2000;
18
107-116 (IV)
-
4
Schaefer M, Schmidt F, Folwaczny C. et al .
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Hepatology.
2003;
37
443-451 (IIa)
-
5
Musselman D L, Lawson D H, Gumnick J F. et al .
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
N Engl J Med.
2001;
344
961-966 (Ib)
-
6
Schafer M, Boetsch T, Laakmann G.
Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C.
Addiction.
2000;
95
1101-1104 (IV)
-
7
Dobmeier M, Frick E, Frank S. et al .
Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha?.
Pharmacopsychiatry.
2000;
33
72-74 (IV)
-
8
Toth C M, Pascual M, Chung R T. et al .
Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal tranplantation.
Transplantation.
1998;
66
1254-1258 (IV)
-
9
Durlik M, Gaciong Z, Rancewicz Z. et al .
Renal allograft function in patients with chronic viral hepatitis B and C treated with interferon alpha.
Transplant Proc.
1995;
27
958-959 (III)
-
10
Rostaing L, Izopet J, Baron E. et al .
Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.
Transplantation.
1995;
59
1426-1431 (IV)
-
11
Magnone M, Holley J L, Shapiro R. et al .
Interferon-alpha induced acute renal allograft rejection.
Transplantation.
1995;
59
1068-1070 (IV)
-
12
Dalgard O, Bjoro K, Hellum K. et al .
Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy.
J Intern Med.
2002;
251
400-406 (Ib)
-
13
Marcellin P, Pouteau M, Benhamou J P.
Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction.
J Hepatol.
1995;
22
364-369 (III)
-
14
Downs A M, Dunnill M G.
Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C.
Clin Exp Dermatol.
2000;
25
351-352 (IV)
-
15
Georgetson M J, Yarze J C, Lalos A T. et al .
Exazerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis.
Am J Gastroenterol.
1993;
88
1756-1758 (IV)
-
16
Berger L, Descamps V, Marck Y. et al .
Alpha interferon-induced eczema in atopic patients infected by hepatitis C virus: 4 case reports.
Ann Dermatol Venereol.
2000;
127
51-55 (IV)
-
17
Tahan V, Ozseker F, Guneylioglu D. et al .
Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature.
Dig Dis Sci.
2003;
48
169-173 (IV)
-
18
Pohl J, Stremmel W, Kallinowski B.
Pulmonal sarcoidosis: A rare side effect of interferon-alpha treatment for chronic hepatitis C infection.
Z Gastroenterol.
2000;
38
951-955 (IV)
-
19
Krehmeier H, Egberts E H.
Sarcoidosis after interferon-alpha treatment in hepatitis C.
Dtsch Med Wochenschr.
2001;
126
460 (IV)
-
20
Nemesanszky E, Pusztay M, Csepregi A.
Effects of interferon treatment on the glucose metabolism of patients with chronic hepatitis C.
Eur J Intern Med.
2000;
11
151-155 (III)
-
21
Konrad T, Vicini P, Zeuzem S. et al .
Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease.
Exp Clin Endocrinol Diabetes.
1999;
107
343-349 (IIb)
-
22
Li C K, Chan P K, Ling S C. et al .
Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major.
Br J Haematol.
2002;
117 (3)
755-758 (III)
-
23
Telfer P T, Garson J A, Whitby K. et al .
Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients.
Br J Haematol.
1997;
98
850-855 (III)
-
24
Swaim M W, Agarwal S, Rosse W F.
Successful treatment of hepatitis C in sickle-cell disease.
Ann Intern Med.
2000;
133
750-751 (IV)
-
25
Ono K, Sata M, Murashima S. et al .
Biological responses to administered interferon in alcoholics.
Alcohol Clin Exp Res.
1996;
20
1560-1563 (III)
-
26
Ohnishi K, Matsuo S, Matsutani K. et al .
Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers.
Am J Gastroenterol.
1996;
91
1374-1379 (IIa)
-
27
National Institutes of Health Consensus Development Conference Panel statement. Management of hepatitis C.
Hepatology.
1997;
26 (Suppl. 1)
2S-10S (III)
-
28
EASL I nternational Consensus Conference on Hepatitis C.
Consensus statement.
J Hepatol.
1999;
30
956-961 (III)
-
29
Sherman M.
Management of viral hepatitis: clinical and public health perspectives - a consensus statement.
Can J Gastroenterol.
1997;
11
407-416 (III)
-
30
Ho S B, Nguyen H, Tetrick L L. et al .
Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population.
Am J Gastroenterol.
2001;
96
157-164 (III)
-
31
Farci P, Alter H J, Govindarajan S. et al .
Lack of protective immunity against reinfection with hepatitis C virus.
Science.
1992;
258
135-140 (IIa)
-
32
Davis G L, Rodrigue J R.
Treatment of chronich hepatitis C in active Drug users.
N Engl J Med.
2001;
345
23 (IV)
-
33
Edlin B R, Seal K H, Lorvick J. et al .
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?.
N Engl J Med.
2001;
345
211-214 (IV)
-
34
Kochar D M, Penner J D, Knudsen T B.
Embryotoxic, teratogenic and metabolic effects of ribavirin in mice.
Toxicol Appl Pharmacol.
1980;
52
99-112 (IIa)
-
35
Ferm V H, Wilhite C, Kilham L.
Teratogenic effects of ribavirin on hamster and rat embryos.
Teratology.
1978;
17
93-101 (IIa)
-
36
Maddrey W C.
Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Semin Liver Dis.
1999;
19
67-75 (Ia)
-
37
Hegenbarthz K, Maurer U, Kroisel P M. et al .
No evidence for mutagenic effects of ribavirin: report of two normal pregnancies.
Am J Gastroenterol.
2001;
96
2286-2287 (letter) (IV)
-
38
Roberts E A, Yeung L.
Maternal-infant transmission of hepatitis C virus infection.
Hepatology.
2002;
36
106-113 (III)
Prof. Dr. med. W.-H. Schmiegel
Medizinische Klinik, Ruhr-Universität Bochum, Knappschafts-Krankenhaus
In der Schornau 23 - 25
44 892 Bochum
